PositoAI/ US/ Summit Therapeutics Inc.

Summit Therapeutics Inc.

NasdaqGM: SMMT · Healthcare

Positivity Index

#5,866 / 6,775

Global

#3,269 / 3,999

United States

Positivity Score

14,740

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Summit Therapeutics Inc. — Overview & Financial Snapshot

Summit Therapeutics Inc. (NasdaqGM: SMMT) is a Healthcare company, ranked #5,866 of 6,775 companies globally and #3,269 of 3,999 in United States on PositoAI, with a Positivity Score of 14,740. Its market capitalisation is ₹1.17 lakh Cr ($12.34B), P/E ratio is -13.9 and P/B ratio is 19.59. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #7 Impact BioMedical Inc. 26,324 #13 Onconetix, Inc. 25,899 #16 Revelation Biosciences, Inc. 25,763 #17 BioStem Technologies, Inc. 25,743

— Nothing to show —

OpenAI is reading recent news...

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

P/B Ratio 19.59

P/E Ratio -13.9

D/E Ratio 0.03

ROE -192.50%

Owes vs Owns ? 0.16× Low $0.16 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-105.21$-1.11

Forward EPS ₹-111.87$-1.18

Beta -1.52

Market Cap ₹1.17 lakh Cr$12.34B

What these numbers mean →

What does Summit Therapeutics Inc. do?

What is Summit Therapeutics Inc.'s P/E and P/B ratio?

Summit Therapeutics Inc. has a P/E ratio of -13.9 and a P/B ratio of 19.59.

What is Summit Therapeutics Inc.'s debt-to-equity ratio?

Summit Therapeutics Inc. has a debt-to-equity ratio of 0.03.

How much does Summit Therapeutics Inc. owe compared with what it owns?

Summit Therapeutics Inc. owes $0.16 for every $1 it owns (balance sheet Jun 2026), which is low.

What is Summit Therapeutics Inc.'s Positivity rank?

Summit Therapeutics Inc. is ranked #5,866 of 6,775 companies globally and #3,269 of 3,999 in United States on PositoAI, with a Positivity Score of 14,740.

Does Summit Therapeutics Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Summit Therapeutics Inc..

Where can I read the latest news about Summit Therapeutics Inc.?

Recent headlines about Summit Therapeutics Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Summit Therapeutics Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Summit Therapeutics Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.